Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

por Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P J
Publicado 2014

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

por Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., Landewé, R.
Publicado 2015

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blin...

por van der Heijde, D, Fleischmann, R, Wollenhaupt, J, Deodhar, A, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, Mease, P J
Publicado 2014

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

por Mease, P J, Fleischmann, R, Deodhar, A A, Wollenhaupt, J, Khraishi, M, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, van der Heijde, D
Publicado 2014